In a small clinical trial, customized mRNA vaccines against high-risk skin cancers appeared to reduce the risk of cancer recurrence and death by nearly 50 percent over five years when compared with ...

By Kamal Choudhury and Mariam Sunny Jan 20 (Reuters) - Moderna and Merck said on Tuesday their experimental personalized ...

A combination of intismeran autogene and Keytruda significantly prolonged recurrence-free survival in melanoma.

A personalised mRNA vaccine developed by Moderna and Merck shows lasting benefits for patients with high-risk skin cancer.

Moderna and Merck shared five-year study data showing their combined cancer treatment cut the risk of melanoma coming back or ...

If promising results on a skin cancer vaccine from Moderna and Merck lead to a new launch, the Covid-19 era darling's stock ...

Jan 22 (Reuters) - Moderna does not plan to invest in new late-stage vaccine trials because of growing opposition to ...

The safety of mRNA vaccines, hailed as a saviour in the covid-19 pandemic, has been called into question by the US ...

Analysts see greater upside in Novavax, while Moderna carries a ‘Hold’ rating despite stronger gains over the past year. ・Moderna was in focus after updated cancer vaccine data, while Novavax drew ...

A study aimed to compare corneal topographic and specular microscopic parameters both before and after patients received the ...

COVID-19 proved that mRNA vaccines can work. Now, researchers are applying the technology to other diseases. More than half of Americans are fully vaccinated against COVID-19. Many of them received an ...

Moderna MRNA announced that it submitted regulatory filings seeking approval for its seasonal influenza vaccine mRNA-1010 across the United States, European Union, Canada and Australia. These filings ...